<table id="_Ref383589084" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5: Established Drug Interactions Based on Studies with Didanosine Delayed-Release Capsules or Studies with Buffered Formulations of Didanosine and Expected to Occur with Didanosine Delayed-Release Capsules</caption>
<col width="14%"></col>
<col width="19%"></col>
<col width="82%"></col>
<tbody>
<tr>
<td align="center" stylecode="Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Drug</content>
</paragraph>
</td>
<td align="center" stylecode="Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Effect</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Clinical Comment</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>ganciclovir</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>↑didanosine concentration</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>If there is no suitable alternative to ganciclovir, then use in combination with didanosine delayed-release capsules with caution. Monitor for didanosine-associated toxicity.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>methadone</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>↓didanosine concentration</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>If coadministration of methadone and didanosine is necessary, the recommended formulation of didanosine is didanosine delayed-release capsules. Patients should be closely monitored for adequate clinical response when didanosine delayed-release capsules are coadministered with methadone, including monitoring for changes in HIV RNA viral load. Do not coadminister methadone with didanosine pediatric powder due to significant decreases in didanosine concentrations. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>nelfinavir</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>No interaction 1 hour after didanosine</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Administer nelfinavir 1 hour after didanosine delayed-release capsules. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule Lrule Toprule " valign="top">
<paragraph>tenofovir disoproxil</paragraph>
<paragraph>fumarate</paragraph>
</td>
<td align="center" stylecode="Botrule Lrule Toprule " valign="top">
<paragraph>↑didanosine concentration</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>A dose reduction of didanosine delayed-release capsules to the following dosage once daily taken together with tenofovir disoproxil fumarate and a light meal (400 kcalories or less and 20% fat or less ) or in the fasted state is recommended.<sup>a</sup>
</paragraph>
<list listtype="unordered">
<item>
<caption>•</caption>250 mg (adults weighing at least 60 kg with creatinine clearance of at least 60 mL/min)</item>
<item>
<caption>•</caption>200 mg (adults weighing less than 60 kg with creatinine clearance of at least 60 mL/min)</item>
</list>
<paragraph>Patients should be monitored for didanosine-associated toxicities and clinical response.</paragraph>
</td>
</tr>
</tbody>
</table>